Product logins

Find logins to all Clarivate products below.


Urological Devices | Market Insights | Japan | 2022

The deferral or cancellation of nonessential procedures due to the COVID-19 pandemic negatively impacted the Japanese urological device market in 2020; however, the market will show a strong recovery in 2021. Following the short-term impact of the global pandemic, the market will continue to expand through 2030, driven by the increasing prevalence of kidney conditions among Japan’s large aging population. However, market growth will be hindered by the complex regulatory environment in Japan, which will inhibit the availability and uptake of new premium-priced devices to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in Japan across an 11-year period.

Related Medtech Insights Reports

Report
Large-Joint Reconstructive Implants – Market Insights – Japan
Growth in large-joint reconstructive procedure volumes is being driven by favorable demographic trends and increased demand for innovative technologies. However, market expansion is partly…
Report
Trauma Devices – Market Insights – Japan
The Japanese trauma device market will experience marginal growth through 2034, primarily fueled by the adoption of innovative, premium-priced technologies. This upward trend is further supported…
Report
Cardiac Rhythm Management Devices – Market Insights – Japan
The Japanese CRM device market will grow over the forecast period. The introduction of novel products—such as the Aurora EV-ICD and dual-chamber leadless pacemakers—and favorable reimbursement…
Report
Neurovascular Devices – Market Insights – Japan
The Japanese neurovascular device market will experience moderate growth through 2034. This update reflects the impact of recent developments, including the launch of new-generation devices and…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Japan
The Japanese GI endoscopy device market is projected to experience modest expansion through 2034. This growth is driven by favorable treatment and screening guidelines, as well as an aging…